Myeloma: New aspects of biology, prognosis and treatment

Pathology

Volumn 28, Issue 1, 1996, Pages 2-7

  Joshua, Douglas E ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Haematology Society of Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; MELPHALAN; PARAPROTEIN; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; DISEASE COURSE; HUMAN; MULTIPLE MYELOMA; MYELOMA; PLASMA CELL; PROGNOSIS; SHORT SURVEY; STEM CELL TRANSPLANTATION;

EID: 0030058712     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/00313029600169403     Document Type: Article

References (18)

1. Davis LDH. International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA. Lancet 1990; 336: 474-81.
2. Cuzich J, Velez R, Doll R. International variations and temporal trends in mortality from multiple myeloma. Int J Cancer 1983; 32: 13-8.
3. Epstein J. Myeloma phenotype: clues to disease origin and manifestation. Hematol Oncol Clin North Am 1992; 6: 249-56.
4. Bakkus MHC, Heirman C, Van Riet I et al. Evidence that multiple Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326-35.
5. Ralph QM, Brisco MH, Joshua DE et al. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. Blood 1993; 82: 202-6.
6. MacLennan ICM. In which cells does neoplastic transformation occur in myelomatosis? Current Topics Microbiol Immol 1992; 182: 209.
7. Bakkus MH, Van Riet I, Van Camp B. Evidence that clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Hematol 1994; 87: 68-74.
8. Ballester OF, Moscinski LC, Lyman GH et al. High levels of interleukin-6 are associated with low growth fraction in multiple myeloma. Blood 1994; 83: 1903-8.
9. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992; 6: 273-84.
10. Klein B, Zhang XG, Jourdan M et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Ntw 1990; 1: 193-201.
11. Joshua DE, Brown R, Gibson J. Prognostic factors in myeloma: what do they tell us about the pathophysiology of the disease? Leukemia and Lymphoma 1994; 15: 375-81.
12. Boccadoro M, Durie BGM, Frutiger Y et al. Lack of correlation between plasma cell thymidine labelling index and serum B2-microglobulin in monoclonal gammopathies. Acta Haematol 1987; 78: 239-42.
13. Greipp PR, Lust JA, O'Fallon WM. Plasma cell labelling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-7.
14. Joshua DE, Gibson J, Brown RD. Mechanisms of the escape phase of myeloma. Blood Rev 1994; 8: 13-20.
15. Joshua DE, Brown RD, Gibson J. Multiple myeloma: why does the disease escape from plateau phase? Br J Hematol 1994; 88: 667-71.
16. Neri A, Murphy JP, Cro D et al. Ras oncogene mutation in multiple myeloma. J Exp Med 1989; 170: 1715-25.
17. Selvanayagam P, Blic M, Narni GF et al. Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 1988; 71: 30-5.
18. Brown RD, Pope B, Luo XF et al. The oncoprotein phenotype of patients with multiple myeloma. Leukemia and Lymphoma 1994; 16: 147-56.